Clinical Trial Update: Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848 [Phase 1]

View source ↗

Summary

Phase 1 tolerability and pharmacology proof-of-principle study of intranasal AZD8848 in allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• AZD8848

Snippet

Sponsor: AstraZeneca | Conditions: Allergic Rhinitis | Phase 1 | Status: COMPLETED